

Therapies for COVID-19 Update

4.13.2022

Michael McNulty

Emergency Management Director

Kansas Department of Health and Environment

HPOP Direct Ordering Requests

- HHS is moving to allow HPOP to be used for requesting therapeutics in addition to reporting use and inventory
- Direct Ordering Requests will be enabled in HPOP by **April 18, 2022, 9:00 a.m. CT**
- Orders will be validated by KDHE staff prior to actioning by HHS for distribution

Create New Order button enabled

Home \ Providers \

Demo Provider 20

Therapeutic Orders Create New Order

TX-HHS-166594 (03/22/2022 11:46) SUBMITTED >
Total Order Lines: 1

TX-HHS-166593 (03/22/2022 11:43) COMPLETED >
Total Order Lines: 1

TX-HHS-166590 (03/22/2022 11:41) COMPLETED >
Total Order Lines: 1

TX-HHS-163493 (03/18/2022 14:24) COMPLETED >
Total Order Lines: 1

TX-HHS-163429 (03/18/2022 13:59) COMPLETED >
Total Order Lines: 1

Load more...

Therapeutic Inventory

Courses Administered and Available Wastage Transfers

Courses Administered and Available Edit History Save Therapeutic Courses

Therapeutic	Administered	Available	History
Bebtelovimab (0002-7589-01)			5:5 on 03/17 by STEVEN.GRIFFITHS@HHS.GOV
Evusheld (0310-7442-02)			10:10 on 02/28 by KEVIN.CROPPER@HHS.GOV

Provider Details Receiving Address / Hours

Provider Details

Name
Demo Provider 20

Federal PIN State PIN National Provider Identifier (NPI)
HHS123432

Team Provider Group

Provider Type
[18] Pharmacy – independent

Alternative ID Non Public Provider
No

Modules
 Therapeutic Diagnostic

Therapeutic Categories
 Monoclonal Antibody Monoclonal Antibody Special Antiviral Antiviral Special

License License Expiration Date
123456799 01/20/2025

Select Therapeutic

Oracle HPOp - Provider Portal

Partner: HHS Validation Partner Gold Pharmacy Help Feedback steve.griffiths@jhuapl.edu

Gold Pharmacy : Therapeutic

Show All Receiving Address / Hours Contacts External Partners My Feedback Therapeutics News Therapeutic Orders Therapeutic Inventory

Therapeutic Orders [Create New Order](#) **Provider Details** Receiving Address / Hours Support Information

TX-HHS-010690 (03/02/2022 11:41) Total Order Lines: 1	
TX-HHS-010689 (03/02/2022 10:42) Total Order Lines: 1	
TX-HHS-010688 (03/02/2022 10:39) Total Order Lines: 1	
TX-HHS-010686 (03/02/2022 07:51) Total Order Lines: 1	
TX-HHS-010439 (12/21/2021 08:51) Total Order Lines: 1	

Load more...

Therapeutic Inventory

Select Therapeutic

- Paxlovid (0069-1085-30) - [Partner: HHS Validation Partner]**
For the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients
- Molnupiravir [Qty 24] (12345-690-00) - [Partner: HHS Validation Partner]**
ASDF
- Merck Antiviral (12345-123-45) - [Partner: HHS Validation Partner]**

Note - Only Therapeutics which have been allocated will be available to order!

Select the number of Courses

Modules

Submit the Order

Oracle HPoP - Provider Portal Partner: HHS Validation Partner Gold Pharmacy Help Feedback steve.griffiths@jhuapl.edu

Gold Pharmacy : Therapeutic

Show All Receiving Address / Hours Contacts External Partners My Feedback Therapeutics News Therapeutic Orders Therapeutic Inventory

Therapeutic Orders [Create New Order](#) [Provider Details](#) [Receiving Address / Hours](#) [Support Information](#)

TX-HHS-010690 (03/02/2022 11:41)
Total Order Lines: 1

TX-HHS-010689 (03/02/2022 10:42)
Total Order Lines: 1

TX-HHS-010688 (03/02/2022 10:39)
Total Order Lines: 1

TX-HHS-010686 (03/02/2022 07:51)
Total Order Lines: 1

TX-HHS-010439 (12/21/2021 08:51)
Total Order Lines: 1

Review & Confirm

Line No. ↑≡	Therapeutic	Generic Description	Quantity	
1	Paxlovid	For the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients	1 Shipping Units (20 Courses)	<input type="checkbox"/>

[Cancel](#) [Add another therapeutic](#) [Submit](#)

New order will appear

The screenshot displays the Oracle HPOP - Provider Portal interface. The top navigation bar includes the portal name, partner information (HHS Validation Partner, Gold Pharmacy), and user details (Help, Feedback, and user email: steve.griffiths@jhuapl.edu). The main heading is "Gold Pharmacy : Therapeutic". Below this, a horizontal menu lists various sections: Show All, Receiving Address / Hours, Contacts, External Partners, My Feedback, Therapeutics, News, Therapeutic Orders, and Therapeutic Inventory. The "Therapeutic Orders" section is highlighted with a red oval and contains a "Create New Order" button. Below the button, a table lists a new order: TX-HHS-010693 (03/02/2022 18:58) with a "SUBMITTED" status and a right-pointing arrow. The total order lines are listed as 1. To the right of the "Therapeutic Orders" section, there are tabs for "Provider Details", "Receiving Address / Hours", and "Support Information". The "Provider Details" tab is active, showing a "Provider Details" section with an edit icon.

Oracle HPOP - Provider Portal

Partner: HHS Validation Partner Gold Pharmacy Help Feedback steve.griffiths@jhuapl.edu

Gold Pharmacy : Therapeutic

Show All Receiving Address / Hours Contacts External Partners My Feedback Therapeutics News Therapeutic Orders Therapeutic Inventory

Therapeutic Orders [Create New Order](#)

TX-HHS-010693 (03/02/2022 18:58)	SUBMITTED >
Total Order Lines: 1	

Provider Details Receiving Address / Hours Support Information

Provider Details [Edit](#)

Therapeutics Ordering (Until April 15)

The image shows a Google Form titled "KDHE COVID Therapies". The form instructions state: "Please use the below form to request oral antiviral treatments. If you have any issues with the form please contact Justin Hatmaker at justin.hatmaker@KS.gov". There is a link to "Sign in to Google" and a "Learn more" link. A red asterisk indicates that the following fields are required:

- Email *
- Facility Name *
- Requestor Name *
- Requestor Phone Number *
- State PIN (9 digits) *

Each field has a "Your answer" label and a text input area. A note for the State PIN field says: "Note: PIN should begin with 'KSA' followed by 6 alphanumeric characters".

- KDHE is accepting orders for all available therapeutics and will suspend allocating.
- Orders may be throttled based on availability
- Go to <https://forms.gle/y66HCBTqsJNWqxYr6>
- Enter all required information
 - Email
 - Facility Name
 - Requestor Name
 - Requestor Phone Number
 - HPOP State PIN (PIN is assigned to each facility)
 - Select the number of patient courses for the therapy requested
- Select Submit
- If there are any questions, the contact listed will be followed up with by KDHE staff

Extended Expiry Dates on Sotrovimab/Paxlovid

Drug Name	Lot#	Extended Expiry Date
Sotrovimab	658W	08-2022
	XV6W, Y74D, JP9Y, 287F	10-2022
	287X, 432U, 433C, BX3T	11-2022
	9W8S, A39T	03-2023
	BD8F, BC9P, C86N, CC3D, CK9V, D74S	04-2023
	J23C, JJ7J, J67D	06-2023
	MJ8W, ME3Y, MJ8X, ME3Y, NM9X, NM6J, NX3P, PK8J	07-2023
	RM3K, S63E, R97L, S94Y, TE4L	08-2023
Paxlovid	FL4516, FL4517, FR7229	The initial 3 lots were extended from 7/31 to 10/31/22.
	FR9088	4th lot was extended from 8/31 to 11/30/22

HHS Product Return Guidance

- All therapeutic products are property of the USG and must be used in accordance with EUA guidance
- Sites of care cannot donate products to entities outside the U.S. or for use outside the U.S.
- Any returned product will be destroyed, as product integrity cannot be verified
- Non-expired product should not be destroyed. Returns only on damaged product or quality concerns
- HHS guidance is for facilities to retain product as these may be active against future variants
- Doses discarded on site (compromised vial, unused diluted vials, etc) should be recorded in HPOP
- FDA Shelf Life Extension for Therapeutics
 - Discussions between ASPR and FDA continue
 - Current information is available at <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/expiration-dating-extension#COVIDtherapeutics>
- For expired therapeutics
 - For REGEN-COV call 844-734-6643
 - For BAM/ETE call 800-821-0538

Sotrovimab Authorization Paused

- Results from in vitro assays used to assess susceptibility of viral variants to particular mAbs suggest that Sotrovimab is not fully active against BA.2 variant
- Centers for Disease Control and Prevention (CDC) estimated the proportion of COVID-19 cases caused by the Omicron BA.2 variant to be above 50% in all U.S. Department of Health and Human Services (HHS) regions
- Due to these data, **use of sotrovimab is not authorized in any U.S. state or territory at this time.**
- Accordingly and effective immediately, ASPR has paused sotrovimab distribution to all U.S. states and territories

Currently Authorized Alternative Treatments


- Paxlovid (an oral antiviral treatment)
- Lagevrio (molnupiravir) (an alternative oral antiviral for patients for which Paxlovid is not appropriate or accessible)
- Bebtelovimab is an alternative monoclonal antibody therapy that is currently authorized and available for distribution
- Based on similar in vitro assay data currently available, these products are likely to retain activity against the BA.2 variant
- All treatment delivery sites can continue ordering Paxlovid, Lagevrio, and bebtelovimab from KDHE
- The FDA recommends that health care providers in all U.S. states and territories use alternative authorized therapy until further notice

UPDATED - Evusheld EUA

- April 1: Evusheld EUA updated to reflect dosage recommendation update to provide additional guidance for administration to patients who received only an initial dose of 300mg (150mg tixagevimab and 150mg cilgavimab)
- No changes to authorized dose for patient who received initial dose of 600mg (300mg tixagevimab and 300mg cilgavimab)
- Revised authorized dosage regimen is:
 - Individuals who received only the previously authorized initial dose of 300mg(150mg of tixagevimab and 150mg of cilgavimab) **should receive an additional Evusheld dose as soon as possible. If a patient received their initial dose:**
 - **Less than 3 months ago**, that patient should receive a dose of 300 mg (150mg of tixagevimab and 150mg of cilgavimab)
 - **More than 3 months ago**, that patient should receive a dose of 600mg (300mg tixagevimab and 300mg cilgavimab)


Kansas Monoclonal Antibody Allocations

WEEK	Bebtelovimab	Evusheld	Sotrovimab
24-Jan	0	624	576
31-Jan	0	640	528
7-Feb	0	416	552
14-Feb	285	432	504
21-Feb	530	432	564
28-Feb	420	432	378
6-Mar	410	432	438
14-Mar	320	432	342
21-Mar	185	432	210
28-Mar	195	432	228
4-Apr	160	432	192
11-Apr	125	432	0




Kansas Oral Antiviral Allocations


Date	Molnupiravir	Paxlovid
24-Jan	1410	350
31-Jan	1410	350
7-Feb	1404	350
14-Feb	1404	350
21-Feb	1224	520
28-Feb	1224	520
7-Mar	888	860
14-Mar	912	860
21-Mar	360	880
28-Mar	336	860
4-Apr	360	860
11-Apr	360	880




Courses Used per Week (Wed – Tues)



Inventory by Product by Date




% Utilization by Product




Utilization by Product

Over the last 1 week (n=349)




Over the last 2 week (n=673)




Reporting Requirements

For Sotrovimab, bam/ete, REGEN-COV



Reporting required by 11:59 pm each Wednesday

For Evusheld, Paxlovid, Molnupiravir, Bebtelovimab



Reporting required by 11:59 pm daily

Sites administering/dispensing USG-purchased COVID-19 therapeutics must provide information on product utilization and stock on hand

Unclassified / For Public Distribution

HHS Clinical Therapy Sessions

- Federal COVID-19 Response: COVID-19 Therapeutics Clinical Webinar
 - Every other Friday (11:00-12:00PM CT); Next Offering – April 15
 - <https://hhsasproea.zoomgov.com/j/1617536991?pwd=NjFMcnJOUENuSFhtRF FtaWltejYzZz09>
- Medical Professionals COVID-19 Roundtable
 - Every other Friday (11:00-12:00PM CT); Next Offering – April 22
 - Email [COVID19Therapeutics @hhs.gov](mailto:COVID19Therapeutics@hhs.gov) if you'd like to join this session

Therapeutic Distribution Locator for Provider Use

Therapeutic Distribution Locator for Provider Use

State, Territory, or Jurisdiction: Kansas
Therapeutic Selector: All

Locations: 433

Use search glass below to find locations near an address.

ADVENTHEALTH OTTAWA HOSPITAL
1301 S MAIN ST, OTTAWA, KS 66067
Evusheld, Product #00310-7442-02
46 Available

ADVENTHEALTH OTTAWA HOSPITAL
1301 S MAIN ST, OTTAWA, KS 66067
Bebtelovimab, Product #00002-7589-01
24 Available

ADVENTHEALTH SHAWNEE MISSION HSPTL
9100 W 74th ST, Shawnee Mission, KS 66204
Bebtelovimab, Product #00002-7589-01
12 Available
Inventory has not been reported in the last 2 weeks. Please contact provider to make sure product is available.

ALLEN COUNTY HOSPITAL
3066 N Kentucky ST, IOLA, KS 66749
Bebtelovimab, Product #00002-7589-01
15 Available

ALLEN COUNTY HOSPITAL
3066 N Kentucky ST, IOLA, KS 66749
Evusheld, Product #00310-7442-02
23 Available

AMBERWELL ATCHISON
800 RAVEN HILL DR, ATCHISON, KS 66002
Bebtelovimab, Product #00002-7589-01
9 Available

AMBERWELL ATCHISON
800 RAVEN HILL DR, ATCHISON, KS 66002
Evusheld, Product #00310-7442-02
24 Available

Evusheld Available: 3,043

Lagevrio (molnupiravir) Available: 10,299

Paxlovid Available: 3,815

Bebtelovimab Available: 1,255

Esri, HERE, Garmin, FAO, NOAA, USGS, EPA, NPS | CDC, HHS
Powered by Esri

<https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/>

Test to Treat Locator

- New Test to Treat locator site launched Wed, 3/30
- <https://covid-19-test-to-treat-locator-dhhs.hub.arcgis.com/>
- Identifies all Test to Treat program sites
- Call center also available: 1-800-232-0233 to get help in English, Spanish, and more than 150 other languages – 8am to midnight ET, 7 days a week
- Disability Information and access Line (DIAL) also available to specifically help those with disabilities access services. 1-888-677-1199. Monday-Friday from 9am to 8pm ET or DIAL@usaginganddisability.org

Find COVID-19 Medication

Kansas, USA

0 250 mi 250

Results: 605

> Locations with testing, medical visits, and medication (Test-to-Treat)	55
> Locations to fill a prescription	550

How to get medication

1. Locations to get testing, medical visits, and medication (Test-to-Treat)
Some pharmacy clinics and health centers can prescribe and give you medication at the same location.
[Learn more about the Test-to-Treat program.](#)
2. Locations to fill a prescription
Any healthcare provider can evaluate and prescribe you COVID-19 medication just as they normally would. You can fill those prescriptions at any location in this tool.

Esri, HERE, Garmin, FAO, NOAA, USGS, EPA | HHS
Powered by Esri

Helpful Therapy Resources

- Side-by-Side Overview of Therapeutics Authorized or Approved for the Prevention of COVID-19 Infection or Treatment of Mild-Moderate COVID-19
 - <https://aspr.hhs.gov/COVID-19/Therapeutics/Documents/side-by-side-overview.pdf>
- Federal Response to COVID-19: Therapeutics Clinical Implementation Guide
 - <https://aspr.hhs.gov/COVID-19/Therapeutics/Documents/USG-COVID19-Tx-Playbook.pdf>
- COVID Therapeutics Decision Aid
 - <https://www.phe.gov/emergency/events/COVID19/therapeutics/Documents/COVID-Therapeutics-Decision-Aid.pdf>

Therapies Questions

- If you have any questions related to monoclonal antibody distribution in Kansas, please contact Michael McNulty (mike.mcnulty@ks.gov)
- Issues with Logging into and using HPOP – 833-748-1979 or cars_helpdesk@cdc.gov